Molecular biology of bone remodeling: Implications for new therapeutic targets for osteoporosis

Maturitas

Volumn 65, Issue 4, 2010, Pages 301-307

  Gallagher, J Chris ^a   Sai, A J ^a  

^a CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bone remodeling; Novel therapies; Osteoporosis

Indexed keywords

ACE 011; AMG 167; ANABOLIC AGENT; CATHEPSIN K INHIBITOR; DENOSUMAB; GLUCAGON LIKE PEPTIDE 2; L 000845704; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; SCLEROSTIN; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; WNT PROTEIN;

BONE REMODELING; CLINICAL TRIAL; DRUG TARGETING; HUMAN; MOLECULAR BIOLOGY; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; REVIEW; SIGNAL TRANSDUCTION;

BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; HUMANS; OSTEOPOROSIS;

ANIMALIA;

EID: 77649183118     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2010.01.002     Document Type: Review

References (42)

1. U.S. Department of Health and Human Services. Bone health and osteoporosis: a report of the surgeon general (2004), Rockville, MD, U.S. Department of Health and Human Services, Office of the Surgeon General
2. Elffors I., Allander E., Kanis J.A., et al. The variable incidence of hip fracture in southern Europe: the MEDOS Study. Osteoporos. Int. 4 September (5) (1994) 253-263
3. Gallagher J.C., Melton L.J., Riggs B.L., and Bergstrath E. Epidemiology of fractures of the proximal femur in Rochester, Minnesota. Clin. Orthop. Relat. Res. 150 July-August (1980) 163-171
4. Cooper C., Atkinson E.J., Jacobsen S.J., O'Fallon W.M., and Melton III L.J. Population-based study of survival after osteoporotic fractures. Am. J. Epidemiol. 137 May (9) (1993) 1001-1005
5. Chapter 1: a public health approach to promote bone health. Available at: http://www.surgeongeneral.gov/library/bonehealth/chapter_1.html#TheMagnitudeoftheProblem; 2009 [accessed 14.09.09].
6. Boyle W.J., Simonet W.S., and Lacey D.L. Osteoclast differentiation and activation. Nature 423 May (6937) (2003) 337-342
7. Hofbauer L.C., and Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 292 July (4) (2004) 490-495
8. Lacey D.L., Timms E., Tan H.L., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 April (2) (1998) 165-176
9. Ott S.M. Sclerostin and Wnt signaling-the pathway to bone strength. J. Clin. Endocrinol. Metab. 90 December (12) (2005) 6741-6743
10. Jackson A., Vayssiere B., Garcia T., et al. Gene array analysis of Wnt-regulated genes in C3H10T1/2 cells. Bone 36 April (4) (2005) 585-598
11. Pacifici R., Brown C., Puscheck E., et al. Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc. Natl. Acad. Sci. U.S.A. 88 June (12) (1991) 5134-5138
12. Gallagher J.C., Goldgar D., and Moy A. Total bone calcium in normal women: effect of age and menopause status. J. Bone Miner. Res. 2 December (6) (1987) 491-496
13. Taxel P., Kaneko H., Lee S.K., Aguila H.L., Raisz L.G., and Lorenzo J.A. Estradiol rapidly inhibits osteoclastogenesis and RANKL expression in bone marrow cultures in postmenopausal women: a pilot study. Osteoporos. Int. 19 February (2) (2008) 193-199
14. Chesnut Jr. C.H., Silverman S., Andriano K., et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am. J. Med. 109 September (4) (2000) 267-276
15. Jilka R.L., O'Brien C.A., Ali A.A., Roberson P.K., Weinstein R.S., and Manolagas S.C. Intermittent PTH stimulates periosteal bone formation by actions on post-mitotic preosteoblasts. Bone 44 February (2) (2009) 275-286
16. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 344 19 (2001 May 10) 1434-1441
17. Keaveny T.M., Donley D.W., Hoffmann P.F., Mitlak B.H., Glass E.V., and San Martin J.A. Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. J Bone Miner Res. 22 1 (2007 Jan) 149-157
18. Subbiah V., Madsen V.S., Raymond A.K., Benjamin R.S., and Ludwig J.A. Of mice and men: divergent risks of teriparatide-induced osteosarcoma. Osteoporos. Int. July (2009)
19. Hurtel-Lemaire A.S., Mentaverri R., Caudrillier A., et al. The calcium-sensing receptor is involved in strontium ranelate-induced osteoclast apoptosis. New insights into the associated signaling pathways. J. Biol. Chem. 284 January (1) (2009) 575-584
20. Atkins G.J., Welldon K.J., Halbout P., and Findlay D.M. Strontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response. Osteoporos. Int. 20 April (4) (2009) 653-664
21. Meunier P.J., Roux C., Seeman E., et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N. Engl. J. Med. 350 January (5) (2004) 459-468
22. Reginster J.Y., Seeman E., De Vernejoul M.C., et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J. Clin. Endocrinol. Metab. 90 May (5) (2005) 2816-2822
23. Gelb B.D., Shi G.P., Chapman H.A., and Desnick R.J. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 273 August (5279) (1996) 1236-1238
24. Gowen M., Lazner F., Dodds R., et al. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J. Bone Miner. Res. 14 October (10) (1999) 1654-1663
25. Peroni A., Zini A., Braga V., Colato C., Adami S., and Girolomoni G. Drug-induced morphea: report of a case induced by balicatib and review of the literature. J. Am. Acad. Dermatol. 59 July (1) (2008) 125-129
26. Bone H.G., McClung M.R., Roux C., et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J. Bone Miner. Res. October (2009)
27. Schlemmer A., and Hassager C. Acute fasting diminishes the circadian rhythm of biochemical markers of bone resorption. Eur. J. Endocrinol. 140 April (4) (1999) 332-337
28. Gottschalck I.B., Jeppesen P.B., Hartmann B., Holst J.J., and Henriksen D.B. Effects of treatment with glucagon-like peptide-2 on bone resorption in colectomized patients with distal ileostomy or jejunostomy and short-bowel syndrome. Scand. J. Gastroenterol. 43 11 (2008) 1304-1310
29. Henriksen D.B., Alexandersen P., Hartmann B., et al. Disassociation of bone resorption and formation by GLP-2: a 14-day study in healthy postmenopausal women. Bone 40 March (3) (2007) 723-729
30. Henriksen D.B., Alexandersen P., Hartmann B., et al. Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. Bone 45 November (5) (2009) 833-842
31. Cummings S.R., San Martin J., McClung M.R., et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 361 August (8) (2009) 756-765
32. Bekker P.J., Holloway D., Nakanishi A., Arrighi M., Leese P.T., and Dunstan C.R. The effect of a single dose of osteoprotegerin in postmenopausal women. J. Bone Miner. Res. 16 February (2) (2001) 348-360
33. Murphy M.G., Cerchio K., Stoch S.A., et al. Effect of L-000845704, an alphaVbeta3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J. Clin. Endocrinol. Metab. 90 April (4) (2005) 2022-2028
34. Frattini A., Orchard P.J., Sobacchi C., et al. Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis. Nat. Genet. 25 July (3) (2000) 343-346
35. Frattini A., Pangrazio A., Susani L., et al. Chloride channel ClCN7 mutations are responsible for severe recessive, dominant, and intermediate osteopetrosis. J. Bone Miner. Res. 18 October (10) (2003) 1740-1747
36. Sheng M.H., and Lau K.H. Role of protein-tyrosine phosphatases in regulation of osteoclastic activity. Cell Mol. Life Sci. 66 June (11-12) (2009) 1946-1961
37. Gardner J.C., van Bezooijen R.L., Mervis B., et al. Bone mineral density in sclerosteosis; affected individuals and gene carriers. J. Clin. Endocrinol. Metab. 90 December (12) (2005) 6392-6395
38. Ai M., Heeger S., Bartels C.F., Schelling D.K., and Osteoporosis-Pseudoglioma Collaborative Group. Clinical and molecular findings in osteoporosis-pseudoglioma syndrome. Am. J. Hum. Genet. 77 November (5) (2005) 741-753
39. Li X., Ominsky M.S., Warmington K.S., et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J. Bone Miner. Res. 24 April (4) (2009) 578-588
40. Turgeman G., Zilberman Y., Zhou S., et al. Systemically administered rhBMP-2 promotes MSC activity and reverses bone and cartilage loss in osteopenic mice. J. Cell. Biochem. 86 3 (2002) 461-474
41. Tokuhara Y., Wakitani S., Imai Y., et al. Local delivery of rolipram, a phosphodiesterase-4-specific inhibitor, augments bone morphogenetic protein-induced bone formation. J. Bone Miner. Metab. June (2009)
42. Ruckle J., Jacobs M., Kramer W., et al. Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. J. Bone Miner. Res. 24 April (4) (2009) 744-752